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Background. Racial diﬀerences in breast cancer survival may be in part due to variation in patterns of care. To better understand
factors inﬂuencing survival disparities, we evaluated patterns of receipt of adjuvant chemotherapy among 2,234 women with
invasive, nonmetastatic breast cancer treated at the Henry Ford Health System (HFHS) from 1996 through 2005. Methods.
Sociodemographic and clinical information were obtained from linked datasets from the HFHS, Metropolitan Detroit Cancer
Surveillance Systems, and U.S. Census. Comorbidity was measured using the Charlson comorbidity index (CCI), and economic
deprivation was categorized using a neighborhood deprivation index. Results. African American (AA) women were more likely
thanwhitestohaveadvancedtumorswithmoreaggressiveclinicalfeatures,tohavemorecomorbidityandtobesocioeconomically
deprived. While in the unadjusted model, AAs were more likely to receive chemotherapy (odds ratio (OR) 1.22, 95% conﬁdence
interval (CI) 1.02–1.46) and to have a delay in receipt of chemotherapy beyond 60 days (OR 1.68, 95% CI, 1.26–1.48), after
multivariable adjustment there were no racial diﬀerences in receipt (odds ratio (OR) 1.02, 95% conﬁdence interval (CI) 0.73–
1.43), or timing of chemotherapy (OR 1.18, 95 CI, 0.8–1.74). Conclusions. Societal factors and not race appear to have an impact
on treatment delay among African American women with early breast cancer.
1.Background
Despite improvements in available options for breast cancer
treatment, there continues to be a considerable gap in
survival between African American (AA) and white women
with breast cancer [1–11]. In 2008, age-adjusted breast
cancer incidence rates for white women were 129.5 per
100,000, compared to 125.6 per 100,000 for AA women,
while 5-year breast cancer relative survival rates for the years
2001 through 2007 were 91.4% for white women and 77.4%
for AA women http://seer.cancer.gov/csr/1975 2008/.R a c i a l
disparities in survival are even more pronounced among
women diagnosed with advanced stages of disease: 5-year
survival for whites versus AA of 85.2% versus 72.1% for
regional, and 24.9% versus 15% for distant stage, compared
to 99.3% versus 92.6% for women with local stage disease
[12]. The Detroit metropolitan area has the lowest 5- and
10-year breast cancer speciﬁc survival rates compared with
10 other sites in the surveillance, epidemiology, and end
results program (SEER) [7], as well as one of the largest AA
populations, making Detroit an ideal area in which to study
factorsinﬂuencingracialdiﬀerencesinbreastcancersurvival.
Adjuvant chemotherapy and hormonal therapy have had
a dramatic impact on breast cancer survival, and in order
to optimize longevity, it is critical for patients to receive
treatment according to standard clinical guidelines [13, 14].2 International Journal of Breast Cancer
Previous reports on patterns of care have indicated that
AA women are less likely to receive standard breast cancer
treatment compared with white women [2, 5, 6, 8, 15–17].
Disparities in receipt of treatment have been shown to be
associated with both lack of referral to specialists, and/or
other barriers including ﬁnancial and sociodemographic
issues [4, 18]. In regards to adjuvant chemotherapy, studies
have shown that comorbidity and low socioeconomic status
both negatively inﬂuence receipt of adjuvant chemotherapy
[7, 19] and others have highlighted the impact of treatment
delay [8, 20, 21] or receipt of nonstandard chemotherapy
regimens [15, 19, 20] as factors associated with inadequate
care.
We hypothesized that racial disparities in breast cancer
survival may be at least in part due to diﬀerences in the
receipt of standard adjuvant chemotherapy as deﬁned by
national treatment guidelines. In order to address this ques-
tion, we evaluated patterns of breast cancer care provided at
the Henry Ford Health System (HFHS), a large integrated
health system serving southeastern MI. The goal of this
study was to assess patterns of adjuvant chemotherapy
administration among women with invasive, nonmetastatic
breast cancer comparing AA and white women, and focusing
on receipt of standard chemotherapy, duration of treatment,
and timing of treatment in relationship to diagnosis.
2. Methods
2.1. Study Design. This study consisted of a descriptive
analysis of adjuvant chemotherapy received by AA and white
women diagnosed with invasive, nonmetastatic breast cancer
at the HFHS between January 1, 1996 and December 31,
2005. HFHS is a large urban integrated health system located
in southeast Michigan founded in 1915 to provide for the
health care needs of the city of Detroit and surrounding
metropolitan area. HFHS currently consists of 5 hospitals,
anchored by Henry Ford Hospital, a 903 bed tertiary care,
research and teaching facility; and 36 ambulatory care
facilities including 5 sites located within the city of Detroit,
and 31 sites located in Wayne (outside of Detroit), Macomb,
Oakland, and Washtenaw counties. A single lifetime medical
record number (MRN) is used throughout the system to
provide continuity of record keeping and medical care.
For the purposes of this project, patient sociodemographic,
clinical, and treatment information was derived through
analyses of linked datasets using the HFHS administrative
databases, the Metropolitan Detroit Cancer Surveillance
System (MDCSS), and the U.S. Census Bureau. The MDCSS
is home for the Detroit SEER registry, which registers all
cancers of residents from Wayne, Oakland, and Macomb
counties.
In the current study, case records were matched from the
SEER and HFHS databases using MRN, social security num-
ber(SSN),lastname,anddateofbirth.Recordsthatmatched
for only one variable were manually reviewed to look for
character or punctuation errors in other nonmatched ﬁelds.
Matching resulted in 3,630 record matches. We excluded
matches with unknown American Joint Cancer Committee
(AJCC) stage (n = 51); ﬁrst breast surgery at another
institution (n = 147); history of a prior malignancy within
6 months of breast cancer diagnosis (n = 52); duplicate
records (n = 3); histology code indicating non-breast origin
(n = 1); stage IV disease (n = 978), other race (n = 45); no
deﬁnitivebreastsurgery(n = 52);andreceiptofneoadjuvant
chemotherapy (n = 67). These exclusions resulted in a study
population of 2,234 (61.5%) white and AA women treated
for invasive, nonmetastatic breast cancer at the HFHS.
2.2. Measurement of Variables. Detailed information on
breast cancer treatment, clinical, and socio-demographic
data were derived from the HFHS and SEER database and
information on neighborhood-level economic deprivation
(see deprivation index below) was obtained form the U.S.
Census Bureau. All primary breast surgery consisting of
lumpectomy (partial mastectomy) or mastectomy (mod-
iﬁed radical mastectomy, radical mastectomy, or simple
mastectomy) and standard axillary lymph node dissection
was performed at the HFHS. Guidelines from the National
Comprehensive Cancer Network (NCCN) corresponding to
the years of diagnosis were used to deﬁne standard adju-
vant chemotherapy treatment recommendations according
to AJCC stage [22–24]. Data on type of chemotherapy,
number of chemotherapy cycles, and dates of diagnosis and
chemotherapy administration were used to assess whether
or not each patient received standard NCCN recommended
adjuvant chemotherapy and the timing of treatment.
Patient and clinical characteristics included race (from
the medical record listing), age at diagnosis, tumor size,
lymph node positivity, histology, grade, and estrogen and
progesterone receptor (ER and PR) status. Insurance status
was available from the HFHS records and was classiﬁed
based on the most frequent insurance charged for each
treatment visit, and categorized into 3 groups (private,
Medicare, and other, including uninsured). Comorbidity
was assessed using the Charlson comorbidity index (CCI)
a prospectively veriﬁed method for classifying comorbid
medical conditions which could aﬀect the risk of mortality
in longitudinal studies [25, 26]. CCI was calculated using
all medical diagnoses for 1 year prior, through one-month
post-breast cancer diagnosis. Economic deprivation was
measured through the use of a composite measure at the
census tract level using a modiﬁcation of the material
deprivation index of Klassen et al., which is more robust
than poverty measures [27]. The material deprivation index
captures multiple dimensions of the economic and social
conditions of neighborhoods, as well as the social isolation
of the residents. The variables included in the index are
deﬁned as (1) the proportion of households with no vehicle
available; (2) proportion of households with no telephone
available; (3) proportion of the population 16 years of
age and older that is unemployed; (4) proportion of the
population living in a crowded residence (more than 1
person per room); and (5) proportion of the population
living below the poverty level. The data are contained in
the 2000 US Census Bureau Summary File 3, Summary
Level 140, Tables H44, H43, P43, H20, and P87, respectively,International Journal of Breast Cancer 3
[http://www.ncbi.nlm.nih.gov/pubmed/15313082/]. The in-
dex is calculated by adding the value of each variable and
dividing by ﬁve in order to produce a single index value,
range 0 to 1, with 0 representing no economic deprivation
and 1 absolute deprivation. For the purpose of our analysis,
DI was categorized into quintiles, based on the distribution
of deprivation in the tricounty area (Q1 < 0.022, 0.022 ≤ Q2
< 0.035, 0.035 ≤ Q3 < 0.056, 0.056 ≤ Q4 < 0.142, 0.142 ≤ Q5
< 0.531).
2.3. Statistical Analysis. The clinical and sociodemographic
characteristics of AA and white women with invasive, non-
metastatic breast cancer were compared by chi-square tests
for categorical variables and Student’s t-tests for continuous
variables. Separate analyses were conducted to determine
racial diﬀerences in the use of standard chemotherapy (yes
versus no), timing of chemotherapy as determined by the
date of diagnosis and the date of chemotherapy initiation
(dichotomized using the sample median, 60 days) for cases
where detailed chemotherapy records were available and
completion of standard chemotherapy (i.e., completing the
NCCN recommended number of cycles of treatment).
Odds ratios (ORs) for receipt of chemotherapy for AA
versuswhitewomenand95%conﬁdenceintervals(CIs)were
estimated using unconditional logistic regression analyses.
Race, age at diagnosis, tumor size, lymph node positivity,
hormone receptor status, tumor grade, CCI, deprivation
index, and insurance status were assessed individually and
in multivariable adjusted models. Unconditional logistic
regression was also used to estimate the odds of beginning
chemotherapy within 60 days of the date of diagnosis. The
analyses consisted of three models, ﬁrst adjusting for clinical
factors only (race, age, tumor size, lymph node positivity,
hormone receptor status, tumor grade, and CCI), second
adjusting for societal factors (race, deprivation index, and
insurance status), and third adjusting for all listed variables.
The purpose of performing three diﬀerent models was to
determine whether clinical versus societal factors had a
greater impact on racial diﬀerences in receipt of adjuvant




Table 1 shows the clinical and socio-demographic character-
istics of women with invasive, non-metastatic breast cancer
in the HFHS study cohort categorized by race. The average
age at diagnosis was 61.2 years (SD 14 years), and the
majority of women were diagnosed with early stage breast
cancer (52.0% were AJCC Stage I and 40.8% were AJCC
Stage II) and 71% were axillary lymph node negative. Most
of the breast tumors were ductal (77%), well or moderately
diﬀerentiated (60%), and ER and/or PR positive (74%),
and roughly 2/3 of the women had no other listed medical
conditions as deﬁned by the CCI. The majority of patients
in the study cohort had lumpectomy or partial mastectomy
(66%), 44% received adjuvant chemotherapy and 51% of the
women had private insurance, followed by Medicare (35%)
and other (4%).
Table 2 shows the proportion of persons or the percent
of households in each quintile of deprivation index by the
parameters used to deﬁne the variable. Individuals living
in the highest quintile (indicating the most deprivation),
quintile 5 (Q5), had 22.5 percent unemployment, compared
with 2.5% in quintile 1. Similarly, for quintile 5, 35% of the
populationlivedunderthepovertylevelcomparedwith2.1%
in quintile 1. For households in quintile 5, almost 30% had
no vehicle, 10% had no telephone, and 10% were deﬁned as
overcrowded. About 40% of the study population lived in a
neighborhood deﬁned by deprivation index quintiles 4 and 5
indicatingthatasizableportionofourstudypopulationlived
in the most socioeconomically deprived neighborhoods.
There were no signiﬁcant racial diﬀerences in age at
diagnosis (Table 1), however, AA women were signiﬁcantly
more likely than white women to have tumors that were
larger size (40 versus 31% ≥ 2.0cm; P<0.001), lymph
node positive (34 versus 27%; P<0.001), ER/PR negative
(29 versus 19%; P<0.001), and poorly diﬀerentiated or
undiﬀerentiated (44 versus 32%; P<0.001). AA women
were more likely compared to white women to have had a
mastectomy (37 versus 32%; P = 0.009) and to have received
adjuvant chemotherapy (48 versus 43%; P = 0.028). AA
women were also more likely to have a higher CCI score, to
live in an area with a higher deprivation index (45% versus
5% resided in quintile 5; P ≤ 0.001), and were less likely to
have private insurance (58 versus 63%: P = 0.020).
Table 3 showstheresultsofthelogisticregressionanalysis
for predictors of receipt of adjuvant chemotherapy. The
unadjusted model for race revealed that AA women were
signiﬁcantly more likely to receive adjuvant chemotherapy
than whites (odds ratio (OR) 1.22, 95% conﬁdence interval
(CI) 1.02–1.46). Other signiﬁcant predictors of receipt of
chemotherapy included tumor size, lymph node positivity,
and ER/PR negativity. Older women and women with Medi-
care or a higher CCI were less likely to receive chemotherapy.
In the model adjusting for all listed predictor variables, race
was no longer a signiﬁcant predictor for receipt of adjuvant
chemotherapy (OR 1.02, 95% CI, 0.73–1.43). In an attempt
to better understand the role of selected clinical versus
societal factors on the eﬀect of race on receipt of adjuvant
chemotherapy, we analyzed two other models, ﬁrst adjusting
for clinical factors alone, and secondly adjusting for societal
factors. In the model adjusting for clinical factors, race was
no longer a signiﬁcant predictor for the receipt of adjuvant
chemotherapy(OR0.90,95%CI,0.69–1.17), however,inthe
model adjusting for only societal factors, the odds of receipt
of chemotherapy for AA versus white women was larger (OR
1.60, 95% CI, 1.26–2.04) than was seen in the unadjusted
model.
Table 4 shows the results of racial diﬀerences in the
use of NCCN standard adjuvant chemotherapy regimens
and timing of chemotherapy administration. There were
no racial diﬀerences in whether an NCCN standard adju-
vant chemotherapy regimen was administered, or in the
completion of the recommended number of chemotherapy
cycles. There was, however, a delay in the initiation of4 International Journal of Breast Cancer






N (%) P value∗
Total 2,234 1,499 735
Age at diagnosis 0.260
<50 526 (23.5%) 346 (23.1%) 180 (24.5%)
50–64 723 (32.4%) 474 (31.6%) 249 (33.9%)
65+ 985 (44.1%) 679 (45.3%) 306 (41.6%)
Mean (std) 61.2 (14.0) 61.6 (13.9) 60.5 (14.1) 0.091
Tumor size <0.001
<2cm 1449 (64.9%) 1010 (67.4%) 439 (59.7%)
2.1–5cm 648 (29.0%) 407 (27.2%) 241 (32.8%)
>5cm 102 (4.6%) 54 (3.6%) 48 (6.5%)
Unknown 35 (1.6%) 28 (1.9%) 7 (1.0%)
Lymph node status <0.001
Negative 1575 (70.5%) 1091 (72.8%) 484 (65.9%)
Positive 659 (29.5%) 408 (27.2%) 251 (34.1%)
AJCC stage 0.001
I 1162 (52.0%) 823 (54.9%) 339 (46.1%)
II 911 (40.8%) 575 (38.4%) 336 (45.7%)
III 161 (7.2%) 101 (6.7%) 60 (8.2%)
ER/PR receptors <0.001
ER+/PR+ 1404 (62.8%) 999 (66.6%) 405 (55.1%)
ER+/PR− 200 (9.0%) 125 (8.3%) 75 (10.2%)
ER−/PR+ 41 (1.8%) 29 (1.9%) 12 (1.6%)
ER−/PR− 496 (22.2%) 280 (18.7%) 216 (29.4%)
Unknown 93 (4.2%) 66 (4.4%) 27 (3.7%)
Histology 0.052
Ductal 1730 (77.4%) 1141 (76.1%) 589 (80.1%)
Lobular 197 (8.8%) 146 (9.7%) 51 (6.9%)
Mixed 134 (6.0%) 98 (6.5%) 36 (4.9%)
Other 173 (7.7%) 114 (7.6%) 59 (8.0%)
Grade <0.001
Well
diﬀerentiated 414 (18.5%) 307 (20.5%) 107 (14.6%)
Moderate/Poor/
Undiﬀerentiated 1725 (77.2%) 1125 (75.1%) 600 (81.6%)
Unknown 95 (4.3%) 67 (4.5%) 28 (3.8%)
Surgery 0.009
Lumpectomy/
Partial Mastectomy 1481 (66.3%) 1021 (68.1%) 460 (62.6%)
Mastectomy 753 (33.7%) 478 (31.9%) 275 (37.4%)
Adjuvant chemotherapy 0.028
No 1247 (55.8%) 861 (57.4%) 386 (52.5%)
Yes 987 (44.2%) 638 (42.6%) 349 (47.5%)
Charlson comorbidity index (CCI)a <0.001
None 1459 (65.3%) 1019 (68.0%) 440 (59.9%)
1 440 (19.7%) 275 (18.3%) 165 (22.4%)
2 136 (6.1%) 82 (5.5%) 54 (7.3%)
3+ 111 (5.0%) 52 (3.5%) 59 (8.0%)







N (%) P value∗
Deprivation indexb <0.001
Q1 420 (18.8%) 406 (27.1%) 14 (1.9%)
Q2 436 (19.5%) 395 (26.4%) 41 (5.6%)
Q3 478 (21.4%) 417 (27.8%) 61 (8.3%)
Q4 501 (22.4%) 211 (14.1%) 290 (39.5%)
Q5 397 (17.8%) 68 (4.5%) 329 (44.8%)
Unknown 2 (0.1%) 2 (0.1%) 0 (0.0%)
Insurance 0.020
Private 1370 (61.3%) 947 (63.2%) 423 (57.6%)
Medicare 780 (34.9%) 503 (33.6%) 277 (37.7%)
Otherc 84 (3.8%) 49 (3.3%) 35 (4.8%)
∗P-value calculations do not include unknown values.
aTheCharlsoncomorbidityindex(CCI)isaprospectivelyveriﬁedmethodforclassifyingcomorbidmedicalconditionswhichcouldaﬀecttheriskofmortality
in longitudinal studies.
bNeighborhood economic deprivation was assessed through a material deprivation index (DI) that captures multiple dimensions of the economic and social
conditionsofneighborhoodsincludingunemployment,poverty,residentialovercrowding,aswellastelephoneandautomobileavailability.Quintile1indicates
less economic deprivation.
cThe other category included 23 self-pay or uninsured, 24 government sponsored MHO, 29 Medicaid, 2 CHAMPUS and 2 insurance pending.
Table 2: Proportion of persons or households in each quintile of deprivation indexa by the ﬁve parameters used to create the deprivation
index.
DI Quintile Unemploymentb No vehiclec Povertyb No
Telephonec Overcrowdingc
Q5 22.5 29.9 35.1 10.4 9.5
Q4 9.2 12.7 14.6 3.4 5.4
Q3 4.8 6.7 6.3 1.5 2.9
Q2 3.7 4.1 3.9 0.7 1.8
Q1 2.5 1.9 2.1 0.4 0.9
aThe deprivation index (DI) is a measure of socioeconomic status that captures multiple dimensions of the economic and social conditions of neighborhoods
including unemployment, poverty, overcrowding, telephone, and automobile availability. The DI can range from 0 to 1, with a value of 0 indicating no
deprivation (i.e., no unemployment, all households have a phone and automobile, no individual lives below poverty, and the presence of households with
more than one room per person, and a value of 1 indicating maximum deprivation.
b%o fp e r s o n s .
c% of households.
adjuvant chemotherapy for AA women compared with white
women. The average time from diagnosis to initiation of
chemotherapy for white women was 67.9 days (S.D. 38.6)
compared to 73.2 (S.D. 36.4) for AA women, P = 0.049.
When time to adjuvant chemotherapy was stratiﬁed at 60
days (the sample median), white women were more likely to
be treated prior to 60 days (55%) compared to AA women
(43%), P<0.001.
Table 5 shows the results of the logistic regression
model evaluating factors that predict timing of adjuvant
chemotherapy administration. Unadjusted analyses showed
that AA women were more likely than white women to
have a delay in receipt of chemotherapy beyond 60 days
(OR 1.68, 95% CI, 1.26–2.23), while in the fully adjusted
model, there were no signiﬁcant racial diﬀerences in time
to chemotherapy initiation (OR 1.18, 95% CI, 0.80–1.74).
Again to better understand the role of selected clinical versus
societal factors on the eﬀect of race on timing of adjuvant
chemotherapy, we analyzed a “clinical model” followed by
a “societal model.” While in the clinical model, AA women
were still more likely to have a delay in receipt of adjuvant
chemotherapy compared to white women (OR 1.77, 95% CI,
1.32–2.38), in the model adjusted for societal factors, race
no longer had a signiﬁcant impact on receipt of adjuvant
chemotherapy (OR 1.15, 95% CI, 0.79–1.67).
4. Discussion
While breast cancer survival rates continue to improve over
time http://seer.cancer.gov/csr/1975 2008/, there remains a
marked discrepancy in survival by race, [1, 3, 4, 11, 12]w i t h
even greater diﬀe r e n c e si ns u r v i v a ls e e nf o rA Aa n dw h i t e
women diagnosed with advanced disease [12]. The availabil-
ity of new adjuvant chemotherapy and hormonal therapy
regimenshavehadanimportantimpactontheimprovement
insurvivalovertime[13,14],however,accesstohigh-quality6 International Journal of Breast Cancer









African American 1.22 (1.02–1.46) 0.88 (0.67–1.14) 1.60 (1.26–2.04) 1.01 (0.72–1.42)
Age at diagnosisa 0.92 (0.91–0.93) 0.91 (0.90–0.92) 0.92 (0.91–0.94)
Large tumorb 4.66 (3.85–5.63) 3.71 (2.81–4.89) 3.76 (2.84–4.98)
Lymph node
positive 8.99 (7.24–11.16) 10.18 (7.54–13.74) 10.28 (7.58–13.94)
ER−/PR− 3.68 (2.97–4.56) 3.49 (2.57–4.74) 3.56 (2.61–4.85)
Moderate/High
grade 3.37 (2.63–4.32) 1.40 (1.00–1.98) 1.44 (1.02–2.04)
CCIc 0.68 (0.61–0.76) 0.93 (0.79–1.10) 0.95 (0.81–1.13)
Deprivation indexd 0.95 (0.89–1.01) 0.91 (0.84–0.99) 0.95 (0.85–1.07)
Medicaree 0.18 (0.15–0.22) 0.18 (0.15–0.22) 0.48 (0.34–0.68)
Other insurancee 0.66 (0.43–1.03) 0.68 (0.44–1.07) 0.43 (0.22–0.85)
∗Models adjusted for all listed variables.
aContinuous variable.
b ≤2cm is the referent.
cCharlson comorbidity index; continuous variable capped at 3.
dQuintiles, the least deprived area (quintile 1) is the referent.
ePrivate insurance is the referent.
Table 4: Racial diﬀerences in the use of standard adjuvant chemotherapy and timing of chemotherapy administration.
Total White African American P value
Standard regimena
No 210 (26.2%) 128 (25.9%) 82 (26.6%)
Yes 593 (73.8%) 367 (74.1%) 226 (73.4%) 0.811
Time to chemotherapyb
0–60 days 405 (50.4%) 274 (55.4%) 131 (42.5%)
>60 days 398 (49.6%) 221 (44.7%) 177 (57.5%) <0.001
Completed the recommended number of cycles or morea,c
No 172 (29.0%) 106 (28.9%) 66 (29.2%)
Yes 421 (71.0%) 261 (71.1%) 160 (70.8%) 0.933
aStandard regimen as deﬁned by the NCCN guidelines as of the date of breast cancer diagnosis.
bTime to chemotherapy based on the time period from date of diagnosis to the date of initiation of adjuvant chemotherapy.
cCalculated only for women who received a standard regimen.









African American 1.68 (1.26–2.23) 1.77 (1.31–2.38) 1.15 (0.79–1.67) 1.18 (0.80–1.74)
Age at diagnosisa 1.01 (1.00–1.03) 1.01 (1.00–1.03) 1.01 (0.99–1.02)
Comorbidity indexb 0.97 (0.79–1.20) 0.87 (0.70–1.08) 0.86 (0.68–1.07)
Mastectomyc 1.45 (1.09–1.92) 1.42 (1.06–1.91) 1.38 (1.02–1.85)
Deprivation indexd 1.27 (1.15–1.40) 1.22 (1.07–1.39) 1.23 (1.08–1.41)
Medicaree 1.73 (1.14–2.61) 1.58 (1.04–2.40) 1.34 (0.81–2.23)
Other insurancee 1.38 (0.64–3.00) 1.11 (0.50–2.43) 1.08 (0.49–2.40)
∗Models adjusted for all listed variables.
aContinuous variable.
bCharlson comorbidity index; continuous variable capped at 3.
cThe reference group is lumpectomy or partial mastectomy.
dQuintiles, the least deprived area (quintile 1) is the referent.
ePrivate insurance is the referent.International Journal of Breast Cancer 7
oncologic care is a key determinant of whether women
receive the recommended standard treatment. It is likely
that racial disparities in the receipt or timing of adjuvant
chemotherapy could have a negative impact on breast cancer
survival.
In this report, we present data on patterns of adjuvant
chemotherapy administration for invasive, nonmetastatic
breast cancer from a large urban health care system where
presumably all individuals who are part of that system
have equal access to the same quality medical care. In
fact, in the unadjusted analysis, AA women were more
likely to receive adjuvant chemotherapy then their white
counterparts, however, this diﬀerence disappeared in the
multivariable adjusted model and was largely accounted for
by the fact that AA women were more likely to present
with larger and more aggressive tumors at diagnosis. Of
particular interest, our unadjusted results demonstrated a
delay in initiation of chemotherapy for AA compared with
whitewomen,however,thisdiﬀerencewasalsoaccountedfor
in the multivariable adjusted model, and largely accounted
for by societal factors. In fact, in the model adjusting for
societal variables, deprivation index and insurance status
oﬀset the eﬀect of race on timing of receipt. In the model
adjustingforclinicalfactors,onlymastectomywasassociated
with chemotherapy delay; however, adjusting for it did not
aﬀect racial diﬀerences in timing. It is understandable that
mastectomy may delay start of chemotherapy, regardless of
race as there may be a longer recovery period compared to
breast conserving surgery. The relationship between societal
factors and delay in receipt of chemotherapy suggest that
while a high-quality medical system is necessary for the
provision of medical care, other related factors such as
poverty and social mobility, can have an important impact
on whether individuals are able to access and beneﬁt from
the medical care system.
Racialdisparitiesinthereceiptofbreastcancertreatment
has been well documented in the literature including studies
revealing disparities in receipt of adjuvant hormonal and
chemotherapy [28], diagnostic and treatment delays [8, 21],
inadequate dosing [7, 8, 15], and receipt of nonstandard
treatment [2]. Others have reported on factors other than
race which impact receipt of treatment and have demon-
strated the relationship between socioeconomic status and
type of treatment [28] and chemotherapy dose [19] and the
inﬂuence of socioeconomic status on breast-cancer-related
mortality [4, 7, 18]. Importantly, the higher prevalence of
comorbid medical conditions seen in AA women has a large
inﬂuence on breast cancer mortality [10, 11]. Our results
are consistent with the literature suggesting that inﬂuences
other than race aﬀect timing of adjuvant chemotherapy,
and highlight the role of poverty and deprivation on timely
receipt of recommended treatment.
Strengths of this study include the inclusion of women
enrolled in a large integrated urban heath care system which
provides uniform access to high-quality medical care. In
addition, the linked HFHS and SEER database allowed for
availability of detailed and accurate clinical, demographic,
andtreatmentdataincludingdetailsonadjuvantchemother-
apyreceived.Ourmeasureofsocioeconomicdeprivationwas
a sophisticated measure developed through the linkage with
U.S.Censusdata,however,thederiveddeprivationindexwas
not based on factors speciﬁc to the individual patient such as
income, education, or family support, and may therefore be
subject to misclassiﬁcation.
In conclusion, race had no direct impact on receipt of
adjuvant chemotherapy or timing of chemotherapy among a
cohort of women treated at a large urban integrated health
care system in Detroit. The fact that AA women were more
likely to receive adjuvant chemotherapy in the unadjusted
model was largely explained by the more advanced stage
at diagnosis among AAs that suggests the need for better
screening and access to early treatment interventions. Delay
in receipt of chemotherapy among AA women was largely
explained by societal factors which likely have a direct eﬀect
on access to care. However, the delay was on average less than
one week and may not have had signiﬁcant clinical impact.
Nevertheless, it serves to remind health care providers of the
importance of making health care accessible to all.
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